Key Takeaways
- Moderna shares rallied approximately 13% to reach $67.50, marking the stock’s strongest close since September 2024, driven by investor day announcements.
- The biotech firm introduced mRNA-6007, its inaugural in vivo CAR-T therapy, designed to treat autoimmune conditions such as lupus, with clinical trials slated to begin in 2027.
- A unanimous 9-0 vote from an FDA advisory committee supported Moderna’s influenza vaccine for individuals aged 50 and above, with final approval anticipated on August 5, 2026.
- Jefferies analyst Andrew Tsai upgraded his price target from $45 to $53, while Piper Sandler’s Edward Tenthoff increased his target to $77, maintaining his Overweight stance.
- The Street’s overall sentiment remains neutral with a Hold rating, featuring a mean price target of $45.42 — suggesting potential downside from present valuations.
Moderna (MRNA) shares experienced a robust rally of approximately 13% on Friday, climbing to $67.50 and positioning the biotech company for its strongest closing price since September 2024. The impressive performance made MRNA the leading gainer within the S&P 500 index during the trading session. Intraday, the stock peaked at nearly 15% gains, approaching the $69 threshold.
The rally was triggered by Moderna’s investor day presentation, during which the company revealed an ambitious expansion of its therapeutic pipeline that extends far beyond its original COVID-19 vaccine franchise.
MRNA has now climbed approximately 42% during the past month, indicating a notable improvement in market confidence.
The centerpiece announcement involved Moderna’s inaugural in vivo CAR-T therapy, designated mRNA-6007. The company intends to initiate clinical trials in 2027, with initial focus on B-cell-driven autoimmune disorders, particularly systemic lupus erythematosus.
In vivo CAR-T technology reprograms a patient’s T-cells directly within the body, offering greater efficiency and reduced costs compared to conventional ex vivo approaches that necessitate cell extraction, laboratory modification, and subsequent reinfusion.
Moderna isn’t pioneering this field in isolation. Eli Lilly made strategic moves earlier this year by acquiring Orna Therapeutics primarily for its in vivo CAR-T capabilities. Lilly shares also rose 6% on Friday, buoyed by separate favorable regulatory news from European authorities concerning its oral oncology treatment.
Strategic Vision Across Three Development Phases
Moderna presented its forward-looking roadmap organized into three separate “horizons.” The initial phase concentrates on advanced, near-commercial assets including current marketed products and advanced-stage development candidates.
Jefferies analyst Andrew Tsai projects the company could successfully commercialize over seven products spanning respiratory, oncology, and rare disease categories within the next two years. This would represent a substantial expansion from its present three-vaccine portfolio.
Tsai highlighted Phase III melanoma trial results anticipated in the latter half of 2026 as a crucial upcoming milestone, characterizing it as “a major event” for shareholder value. He maintains a Hold rating while elevating his price target from $45 to $53.
Another program attracting significant attention is mRNA-4194, Moderna’s pioneering cancer prevention initiative, developed for patients diagnosed with Lynch syndrome. The company is simultaneously progressing mRNA-1195, its experimental multiple sclerosis treatment, which should yield preliminary data later in 2026.
Influenza Vaccine Program Provides Additional Momentum
Beyond oncology and autoimmune therapeutics, Moderna’s experimental influenza vaccine mRNA-1010 received encouraging news when an FDA advisory committee delivered a unanimous 9-0 endorsement for approval in adults aged 50 years and older.
The FDA’s final determination is scheduled for August 5, 2026. Regulatory clearance would provide the company with an additional revenue-generating product beyond its COVID-19 franchise.
Piper Sandler analyst Edward Tenthoff elevated his price target from $69 to $77 while maintaining his Overweight rating, citing the substantial progress showcased during investor day.
Despite optimism from select analysts, the overall Wall Street consensus remains at Hold, reflecting two Buy ratings, 19 Hold ratings, and three Sell ratings accumulated over the previous three months. The consensus price target of $45.42 suggests potential downside exceeding 31% from current trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
